Rana, Z.; Diermeier, S.; Walsh, F.P.; Hanif, M.; Hartinger, C.G.; Rosengren, R.J.
Anti-Proliferative, Anti-Angiogenic and Safety Profiles of Novel HDAC Inhibitors for the Treatment of Metastatic Castration-Resistant Prostate Cancer. Pharmaceuticals 2021, 14, 1020.
https://doi.org/10.3390/ph14101020
AMA Style
Rana Z, Diermeier S, Walsh FP, Hanif M, Hartinger CG, Rosengren RJ.
Anti-Proliferative, Anti-Angiogenic and Safety Profiles of Novel HDAC Inhibitors for the Treatment of Metastatic Castration-Resistant Prostate Cancer. Pharmaceuticals. 2021; 14(10):1020.
https://doi.org/10.3390/ph14101020
Chicago/Turabian Style
Rana, Zohaib, Sarah Diermeier, Fearghal P. Walsh, Muhammad Hanif, Christian G. Hartinger, and Rhonda J. Rosengren.
2021. "Anti-Proliferative, Anti-Angiogenic and Safety Profiles of Novel HDAC Inhibitors for the Treatment of Metastatic Castration-Resistant Prostate Cancer" Pharmaceuticals 14, no. 10: 1020.
https://doi.org/10.3390/ph14101020
APA Style
Rana, Z., Diermeier, S., Walsh, F. P., Hanif, M., Hartinger, C. G., & Rosengren, R. J.
(2021). Anti-Proliferative, Anti-Angiogenic and Safety Profiles of Novel HDAC Inhibitors for the Treatment of Metastatic Castration-Resistant Prostate Cancer. Pharmaceuticals, 14(10), 1020.
https://doi.org/10.3390/ph14101020